NEW YORK, August 7, 2017 /PRNewswire/ --
If you want a Stock Review on DRRX, SCMP, APRI, or MEIP then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. The profitability of individual companies in the Drug Manufacturers space depends on their ability to discover and market new drugs, while demand for pharmaceuticals
Cupertino, California headquartered DURECT Corp.'s shares declined 0.59%, finishing last Friday's session at $1.69. A total volume of 192,719 shares was traded. Over the last month and the previous three months, the stock has advanced 9.74% and 111.25%, respectively. Furthermore, the Company's shares have gained 26.12% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 10.85% and 38.47%, respectively. Additionally, shares of DURECT, which researches and develops medicines based on its epigenetic regulator and drug delivery programs, have a Relative Strength Index (RSI) of 52.23.
On July 12th, 2017, research firm Stifel upgraded the Company's stock rating from 'Hold' to 'Buy' while revising its previous target price from $1.25 a share to $3 a share.
On August 01st, 2017, DURECT announced that, in conjunction with its Q2 2017 financial results press release, the Company will host a conference call on August 08th, 2017, at 4:30 pm ET. A live audio webcast of the presentation will be available under the "Investor Relations" section of the Company's homepage. Your complete research report on DRRX can be retrieved for free at:
On Friday, shares in Rockville, Maryland headquartered Sucampo Pharmaceuticals Inc. ended the session 0.48% higher at $10.40. The stock recorded a trading volume of 469,212 shares, which was above its three months average volume of 443,970 shares. The Company's shares have gained 0.97% in the previous three months. The stock is trading below its 50-day moving average by 0.66%. Moreover, shares of Sucampo Pharma, which focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the US, Japan, Switzerland, and internationally, have an RSI of 42.12.
On July 18th, 2017, Sucampo Pharma announced that Karen Smith, M.D., Ph.D., M.B.A., LLM, has joined the Company's Board of Directors on July 15th , 2017. Dr. Smith is Executive Vice President, R&D, and Chief Medical Officer at Jazz Pharmaceuticals. She brings to the Company over 25 years of senior leadership and executive experience with both major pharmaceutical companies and start-up biotechnology organizations. A free report on SCMP is just a click away at:
San Diego, California headquartered Apricus Biosciences Inc.'s stock climbed 0.74%, to close the day at $1.36 with a total trading volume of 189,101 shares. The Company's shares have advanced 21.43% in the last one month, 18.26% over the previous three months, and 4.62% since the start of this year. The stock is trading 25.15% above its 50-day moving average. Additionally, shares of Apricus Biosciences, which focuses on the development and commercialization of product candidates in the areas of urology and rheumatology, have an RSI of 64.00.
On August 02nd, 2017, Apricus Biosciences reported financial results for Q2 and six months ended June 30th, 2017. For Q2 2017, net loss was $1.5 million, or loss per share of $0.13. For the six months ended June 30th, 2017, net income was $6.6 million, or income per share of $0.69. The Company's cash totaled $7.8 million, as of June 30th, 2017. Sign up for your complimentary research report on APRI at:
Shares in San Diego, California-based MEI Pharma Inc. recorded a trading volume of 283,142 shares. The stock ended at $2.93, jumping 5.40% from the last trading session. The Company's shares have gained 3.53% in the past month, 83.13% over the previous three months, and 103.47% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 19.08% and 62.85%, respectively. Furthermore, shares of MEI Pharma, which focuses on the clinical development of drugs for the treatment of cancer, have an RSI of 58.03.
On August 02nd, 2017, MEI Pharma and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, announced that the first patient has been dosed in the pivotal Phase-3 study of the investigational agent pracinostat in combination with azacitidine in adults with newly diagnosed acute myeloid leukemia and who are unfit to receive intensive induction chemotherapy. The randomized, double-blind, placebo-controlled study will enroll approximately 500 eligible patients worldwide. Sign up for your complimentary research report on MEIP at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...
Antioxidants are artificial or natural components that help protect the human body from the damage ...
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...View All